The global automated microbiology market is expected to grow over the forecast period owing to the increasing prevalence of pathogen-induced diseases. In recent years, the identification of pathogens with the help of automated microbiology has generated huge momentum, as it helps in the early detection of various infectious agents such as parasites, viroid, fungi, prion, bacterium, and viruses. These agents cause severe diseases like rubella, ebola, chickenpox, measles, mumps, influenza, and smallpox. Automated microbiology has gained importance as a result of outbreaks of new diseases as a consequence of adapting and mutating bacteria. The ability to promptly respond to the increasing demand for public health lies in offering accurate, better, and rapid identification of diseases and causative pathogens. Rapid technological advancements are also boosting the growth of this market. For instance, the STEC test by BioControl Systems helps in the detection of non-O157 serotype of e.coli with the help of molecular and food microbiology technology and BacT/ALERT 3D microbial detection system introduced by bioMeriux. As compared to other microbial detection systems, automated microbiology comes along with advantages such as early detection and an easy access system.
The automated microbiology market on the basis of the technology is segmented into DNA sequencing; DNA & RNA probe technology, detection techniques, immunoassays, and monoclonal antibodies. Among these, monoclonal antibodies held the largest market share in 2014, owing to their extensive use to develop the clone of the parent cell which is used in the detection of the infected cell or disease. Furthermore, DNA and RNA probe technology is bifurcated into amplification methods and labeling techniques. Detection techniques is further classified into, non-isotopic methods and radioactive methods. The automated microbiology market is segmented on the basis of end-use into biotechnology industries, clinical laboratories, hospitals, and blood banks. Among these, clinical laboratories held the largest market share in 2014. The major factor attributing to the dominance of this segment is the relatively large number of microbiology researches conducted at laboratories for the detection of various infectious agents.
Geographically, the automated microbiology market is studied with respect to five regions, which are North America, Europe, Asia Pacific, Latin America, and MEA. Among these, North America dominated the market in 2014, owing to the high use of advanced technology in this region, and the introduction of advancements in molecular diagnostic tests such as genetic probes. Over the forecast period, Asia Pacific will witness lucrative growth as the consequence of rapidly improving healthcare infrastructure over the coming seven years. Moreover, the growing demand for technologically advanced products in this region is expected to further boost the growth of this region.
The major players in the automated microbiology market are Becton Dickinson and Company, Bio-Rad Laboratories, Inc., bioMeriux, Inc., QIAGEN GmbH, Beckman Coulter, Agilent Technologies, Inc., Gene-Probe, Inc., Affymetrix, Inc., and Abbott Laboratories.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.